

Technology Advisory Interests Register

Topic: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]

Publication Date: 16 July 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Rhiannon Owen	TAC Committee Member	Direct- financial	Rhiannon has acted as a paid consultant for AstraZeneca offering statistical advice on economic models for Dato-DXd in HR-positive HER2-negative inoperable or metastatic breast cancer on the 31 March 2023.	07/05/2025	It was agreed that Rhiannon's declaration would not prevent them from participating in discussions on this appraisal
David McAllister	TAC Committee Member	Direct – non-financial professional	David's research uses clinical trial data provided by AstraZeneca (among other sponsors) via the Vivli trial repository.	07/05/2025	It was agreed that David's declaration would not prevent them from participating in discussions on this appraisal
Warren Linley	TAC Committee Member	Direct – Financial	Warren has acted as a paid consultant for AstraZeneca offering statistical advice on economic models for Dato-DXd in HR-positive HER2-negative inoperable or metastatic breast cancer on the 31 March 2023.	07/05/2025	It was agreed that Warren's declaration constituted a conflict of interest, and Warren was not able to attend or contribute to the discussions on this appraisal.
David Jackson	Expert	Direct – Financial	David declared the following interests:	07/05/2025	It was agreed that David's declaration would not

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>David has previously been on AstraZeneca sponsored external advisory boards relating to the use of benralizumab for asthma and EGPA.</p> <p>David has previously been an invited speaker at medical educational meetings sponsored by AstraZeneca relating to asthma care</p> <p>In the last 5 years David has been on external advisory boards and have been an invited speaker relating to asthma care for GSK and Sanofi Regeneron.</p>		prevent him from acting as an expert on this appraisal.
David Jackson	Expert	Direct – non-financial	David is the Co-author on MANDARA publication (Benralizumab randomised clinical trial in EGPA, Wechsler et al. NEJM 2024)	07/05/2025	It was agreed that David's declaration would not prevent him from acting as an expert on this appraisal.
David Jackson	Expert	Indirect	David's institution has received a research grant from AstraZeneca relating to asthma (not EGPA)	07/05/2025	It was agreed that David's declaration would not prevent him from acting as an expert on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Leane-Jo Holmes	Expert	Direct – Financial	<p>Leane-Jo declared the following:</p> <p>Consultancy fees from AstraZeneca/GlaxoSmithKlein/Novartis</p> <p>Payment for lectures/presentation from Sanofi, Astra Zeneca, GSK, NAPP & Boehringer Ingelheim</p> <p>Support to attend conference from AstraZeneca, GlaxoSmithKline, Sanofi, Chiesi</p> <p>Advisory board fees from AstraZeneca/GlaskoSmithKlein/TEVA</p>	07/05/2025	It was agreed that Leane-Jo's declaration would not prevent him from acting as an expert on this appraisal.
Leane-Jo Holmes	Expert	Indirect	<p>Leane-Jo declared the following:</p> <p>She has received 2 inhaler sensors from NuvoAir, paid direct to her institute and not to herself</p> <p>Medical writing for TEVA, paid direct to her institute and not to herself</p>	07/05/2025	It was agreed that Leane-Jo's declaration would not prevent him from acting as an expert on this appraisal.